The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Spacewalk is now live on Pendulum. There isn't much to get excited about at the moment with Blu, so we need to celebrate the wins! Let's hope this is the beginning of something beautiful for those of us who are left. Hats off to the clever people who made it happen.
https://twitter.com/pendulum_chain/status/1773004292695150828
I miss the knowledgable posters who helped me make sense of the tech - they seemed to have disappeared but I do hope they 're just having a lie-down and come back.
Well, that's a wrap for Newcrest Mining on the Australian Securities Exchange. See you tomorrow, ASX: NEM.
The wheels are well and truly in motion and let's hope this step is one of the many upcoming which will ultimately lead to brighter futures for us all. Bring it on. ✅
I think there was an error in the Financial Highlights - I believe it meant to state that:
'Cash Reserves at 31 December 2022 were £5,807,000 (31 December 2021: £1,650,000)'
..but instead it said 2021 twice, ie:
'Cash Reserves at 31 December 2021 were £5,807,000 (31 December 2021: £1,650,000)'.
Big error to make in this context especially, but I think it is just a typo.
Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: "I am delighted to further extend our relationship with the University of York and in particular the leading-edge research being a carried out in Professor Dawn Coverley's laboratories. The continuity and commitment of the researchers at the University has been a key building block in the development and commercialization of the CIZ1B biomarker for early cancer diagnosis. The current research programme has met some critical milestones, especially in optimising the platform and antibodies required to scale up and bring to market our diagnostic tests for early stage cancer detection. This new agreement will continue our access to state of the art research facilities and world leading scientists as we pursue our plans to bring early detection tests for lung cancer and potentially other forms of cancer."
New Research Agreement with the University of York for Cancer Diagnosis and Therapy
Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that following successful results from its current research programme with the University of York, due to end this year, that it has today signed a new research agreement with the University for the further development and validation of its CIZ 1B biomarker technology for early stage cancer diagnosis and other potential applications in cancer therapy.
This includes the evaluation of the Company's proprietary biomarker for detecting a range of cancers in addition to the existing programme for early lung cancer detection.
* New 12-month research and development agreement with the University of York
* Builds on successful outcomes of current research programme on meeting key milestones for monoclonal antibody characterization and assay platform optimization
* All intellectual property rights arising from the work to be owned by the Company
* Extends access to state of the art facilities and world leading scientists to support new solutions for early cancer diagnostics and therapeutic tools
This new agreement will extend the work being conducted at the university until 25th September 2024 and follows the successful programme initially announced on 17 September 2021 and further extended to June 2023. With a focus on the development and validation of molecular tools with potential application in cancer diagnosis or therapy, significant progress has been made in characterising and optimizing the company's antibodies for use and scale up into the configuration required for further clinical trials ahead of the launch of commercial early stage lung cancer assays. As in previous agreements, Cizzle Biotechnology will own all intellectual property rights arising from the work which strengthens the Company's position in creating new solutions for early cancer diagnostics and therapeutic tools.
Cizzle Biotechnology was a spin out from the University of York based on research and development by Professor Dawn Coverley at the University and the first company from the university to be listed on the London Stock Exchange. The company has a proven and long-term commitment to work with the University of York which provides access to its leading-edge research facilities and expertise.
Here's a transcript of the video:
As you are aware, the first blast was conducted during this past week at Zulu Lithium. At the moment the ore that has been fragmented as a result of the blast has been moved to the pad and we are anticipating that during the course of this weekend we should be able to start feeding ore to the plant. We are waiting for one reagent to arrive and the reagent should be with us hopefully during the course of the weekend as well but the moment that is there we will be processing throughout the plant and the objective is to produce (video cuts off).
Glad to see this is finally clicking. This is the future and we are lucky enough to be on board early.
Top of the leader board! Nice to see. We'd better get used to it I guess ;)
Most of that went over my head but I'm excited to be along for the ride and learn as I go. Let's hope the March goings-on will give the SP a kick in the right direction!
Thanks for the nudge. That seemed to have done the trick :)
Damn those pesky subscription-only articles. I tried to get around it (to no avail) but did see this lovely mention below in a sub-para from the article when searching. Great to see Havieron being mentioned in mainstream Aussie press in such a positive way:
"Havieron has been touted as one of the best Australian copper-gold discoveries in recent memory."
Whilst doing a search, I just found a couple of news pieces from yesterday on Global Banking and Finance dot com (which is where you can go to find it if the below link doesn't work) and also The Defiant. Looks like they were picked up from a news release via Chainwire as they're both the same. Apologies if this is old news/already shared.
https://www.globalbankingandfinance.com/forex-launches-on-blockchain-as-pendulum-deploys-its-parachain/
Forex-focused layer 1 blockchain Pendulum has announced the successful mainnet launch of its Polkadot parachain. As a result, the Pendulum chain is now connected to the Polkadot ecosystem, allowing businesses & fintechs to enter the world of decentralized finance. The move ushers in a new era for Forex, bringing a multi-trillion dollar market to DeFi.
The deployment of Pendulum’s parachain on Polkadot mainnet marks the first phase of a three-part launch. Subsequent phases will comprise the Token Transferability Event, the Spacewalk Stellar-Polkadot Bridge launch, as well as the launch of forex-AMM 0xAmber, with the entire launch process expected to be completed by March.
etc
The highly anticipated Pendulum Portal is set to go live soon, granting users access to a range of features and services, including staking opportunities and reward claiming for both AMPE and PEN token holders. In addition, the tokens will be transferable freely, enabling seamless transactions.
etc
Also this one:
https://thedefiant.io/forex-launches-on-blockchain-as-pendulum-deploys-its-parachain
Same for me. It was a nice surprise. I am excited for what's next.
This is getting more exciting by the day. I appreciate all that you share.
Love this, but there was clearly a printing error as they forgot Tassie!